Recent

% | $
Quotes you view appear here for quick access.

Celldex Therapeutics, Inc. Message Board

  • neshua10 neshua10 Dec 6, 2012 7:48 PM Flag

    Quite simple.....

    Marucci would not have said during the December 3 webcast, that "..this Saturday is going to be catalyst" in response to the question of "...toward FDA approval and significant investor interest, unless the results were excellent to outstanding

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Except that Marucci didn't say "going to be"; he said "could be" a catalyst.

      Check the transcript.

      Sentiment: Strong Sell

    • I hope you are right, but "catalyst" is a neutral term in the business world - it just means that there will be major clarity coming that have an impact on the business, could be good or bad.

      • 1 Reply to doubledown1967
      • Yes. however in light of 72 hours henceforth, no, no, don't think so, lol Furthermore, what struck me, I know it struck others.. probably as well. you also have to have an attuned/adjusted ear of appreciation for who is at the table speaking, how he (Marucci) is speaking.... etc. If you have listened to him prior interviews/conferences, it is somewhat out of character for him to be so bold as to ostensibly state, "You want a catalyst...well you'll have one here on Saturday." This what he basically said in no uncertain #$%$ to her question.

    • neshua today is a reaction to PFE Breast Cancer drug news,first out of the gate!

      OK?

      An experimental drug showed impressive effectiveness and safety in a mid-stage trial against a common form of advanced breast cancer, lifting Pfizer Inc shares nearly 2 percent.

      The favorable results prompted the drugmaker to plan large late-stage trials of the drug next year. If approved, the medicine could fetch multi-billion dollar sales, industry analysts said.

      The drug, called PD-0332991, delayed by more than 18 months the worsening of symptoms for postmenopausal women with the most common form of breast cancer. Data from the study of the drug was presented on Wednesday at the annual San Antonio Breast Cancer Symposium.

      The medicine, which blocks enzymes known as CDK4 and 6 kinases, was taken in combination with a standard drug called letrozole among women who were estrogen receptor positive - meaning tumors grow in response to estrogen - and HER2-negative, meaning that the HER2 protein is not causing the cancer. Such patients make up about 60 percent of breast cancer cases.

      Patients had either locally advanced tumors or cancer that had spread to other parts of the body.

      Those taking both drugs went an average of 26.1 months before tumors worsened. That compared with 7.5 months for those taking letrozole, but not PD-0332991. The 18.6 month difference was considered statistically significant.

      *************************************************

      different type of Breast Cancer and NO threat to 011!!

      Frank

 
CLDX
4.72-0.05(-1.05%)Jul 28 4:00 PMEDT